Leukaemia
Leukaemia is a cancer that begins in the bone marrow, where blood cells are made. Abnormal white cells multiply out of control, crowding out healthy red cells, platelets, and functional white cells. It is grouped as acute or chronic, and by the cell line involved (lymphoid or myeloid), giving four main subtypes with distinct behaviours and treatment approaches.
Key points
- Bone marrow overproduces faulty white blood cells, leaving too few healthy red cells, platelets and functioning white cells in circulation.
- Chronic forms may progress slowly and allow for careful monitoring, while acute leukaemia usually demands treatment without delay.
- Chemotherapy, including the alkylating agent cyclophosphamide, works by damaging the DNA of rapidly dividing cancer cells and forms the backbone of many treatment regimens.
How leukaemia is managed
Treatment depends on the subtype, how quickly the disease is progressing, and the patient’s overall health. For many subtypes, chemotherapy forms the backbone of care. Cyclophosphamide is a widely used alkylating agent that damages the DNA of rapidly dividing cancer cells and is part of combination regimens for several leukaemia types. Supportive oncology care addresses side effects such as anaemia, infection risk, and fatigue alongside the primary therapy.
Acute forms require prompt treatment; chronic leukaemias, such as CLL, are sometimes monitored closely without immediate intervention if progression is slow. Anyone experiencing unexplained fatigue, easy bruising, persistent infections, or swollen lymph nodes should seek medical evaluation promptly.